Recurrent mutations implicate several epigenetic regulators in the early molecular
pathobiology of myelodysplastic syndromes (MDS). We hypothesized that MDS subtypes …

The potential mechanism of myelodysplastic syndromes (MDS) progressing to acute
myeloid leukemia (AML) remains poorly elucidated. It has been proved that epigenetic …

Deregulated epigenetic mechanisms are likely involved in the pathogenesis of
myelodysplastic syndromes (MDSs). Which genes are silenced by aberrant promotor …

Gene expression profiling signatures may be used to classify the subtypes of
Myelodysplastic syndrome (MDS) patients. However, there are few reports on the global …

Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently
represent an intermediate disease stage before progression to acute myeloid leukemia …

Purpose The current classification systems of myelodysplastic syndromes (MDS), including
the International Prognostic Scoring System (IPSS), do not fully reflect the molecular …

Myelodysplastic syndromes (MDS) are clonal diseases of the elderly characterized by
chronic cytopenias, dysplasia and a variable risk of progression to acute myeloid leukemia …

The prognostic and predictive value of sequencing analysis in myelodysplastic syndromes
(MDS) has not been fully integrated into clinical practice. We performed whole exome …

The myelodysplastic syndromes (MDS) are a group of clonal diseases characterized by
inefficient haematopoiesis, increased apoptosis and risk of evolution to acute myeloid …

Knowledge of the molecular and clonal characteristics in the myelodysplastic syndromes
(MDS) and during progression to acute myeloid leukaemia (AML) is essential to understand …